Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions

Detalhes bibliográficos
Autor(a) principal: Teixeira,Rosângela
Data de Publicação: 2013
Outros Autores: Nascimento,Yone de Almeida, Crespo,Déborah
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Infectious Diseases
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702013000200013
Resumo: The standard of care therapy of chronic hepatitis C with the combination of pegylated interferon and ribavirin for 24 or 48 weeks was a remarkable accomplishment of the past decade. However, sustained virological responses rates of about 80% (genotypes 2-3) and 50% (geno 3 type 1) were not satisfactory especially for patients infected with genotype 1. Important advances in the biology of HCV have made possible the development of the direct-acting antiviral agents boceprevir and telaprevir with substantial increase in the rates of sustained virological response with shorter duration of therapy for a large number of patients. However, the complexity of triple therapy is higher and several new side effects are expected suggesting greater expertise in the patient management. Anemia and disgeusia are frequent with boceprevir while cutaneous rash, ranging from mild to severe, is expected with telaprevir. Higher risk of drug-drug interactions demand further clinical consideration of the previous well-known adverse events of pegylated interferon and ribavirin. Identification and prompt management of these potential new problems with boceprevir and telaprevir are crucial in clinical practice for optimizing treatment and assuring safety outcomes to HCV-genotype 1 patients.
id BSID-1_8f614fc1937b2fc9f7438fbba5686c7e
oai_identifier_str oai:scielo:S1413-86702013000200013
network_acronym_str BSID-1
network_name_str Brazilian Journal of Infectious Diseases
repository_id_str
spelling Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactionsHepatitis CProtease inhibitorsAdverse eventsDrug interactionsThe standard of care therapy of chronic hepatitis C with the combination of pegylated interferon and ribavirin for 24 or 48 weeks was a remarkable accomplishment of the past decade. However, sustained virological responses rates of about 80% (genotypes 2-3) and 50% (geno 3 type 1) were not satisfactory especially for patients infected with genotype 1. Important advances in the biology of HCV have made possible the development of the direct-acting antiviral agents boceprevir and telaprevir with substantial increase in the rates of sustained virological response with shorter duration of therapy for a large number of patients. However, the complexity of triple therapy is higher and several new side effects are expected suggesting greater expertise in the patient management. Anemia and disgeusia are frequent with boceprevir while cutaneous rash, ranging from mild to severe, is expected with telaprevir. Higher risk of drug-drug interactions demand further clinical consideration of the previous well-known adverse events of pegylated interferon and ribavirin. Identification and prompt management of these potential new problems with boceprevir and telaprevir are crucial in clinical practice for optimizing treatment and assuring safety outcomes to HCV-genotype 1 patients.Brazilian Society of Infectious Diseases2013-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702013000200013Brazilian Journal of Infectious Diseases v.17 n.2 2013reponame:Brazilian Journal of Infectious Diseasesinstname:Brazilian Society of Infectious Diseases (BSID)instacron:BSID10.1016/j.bjid.2012.10.010info:eu-repo/semantics/openAccessTeixeira,RosângelaNascimento,Yone de AlmeidaCrespo,Déboraheng2013-05-07T00:00:00Zoai:scielo:S1413-86702013000200013Revistahttps://www.bjid.org.br/https://old.scielo.br/oai/scielo-oai.phpbjid@bjid.org.br||lgoldani@ufrgs.br1678-43911413-8670opendoar:2013-05-07T00:00Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID)false
dc.title.none.fl_str_mv Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions
title Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions
spellingShingle Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions
Teixeira,Rosângela
Hepatitis C
Protease inhibitors
Adverse events
Drug interactions
title_short Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions
title_full Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions
title_fullStr Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions
title_full_unstemmed Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions
title_sort Safety aspects of protease inhibitors for chronic hepatitis C: adverse events and drug-to-drug interactions
author Teixeira,Rosângela
author_facet Teixeira,Rosângela
Nascimento,Yone de Almeida
Crespo,Déborah
author_role author
author2 Nascimento,Yone de Almeida
Crespo,Déborah
author2_role author
author
dc.contributor.author.fl_str_mv Teixeira,Rosângela
Nascimento,Yone de Almeida
Crespo,Déborah
dc.subject.por.fl_str_mv Hepatitis C
Protease inhibitors
Adverse events
Drug interactions
topic Hepatitis C
Protease inhibitors
Adverse events
Drug interactions
description The standard of care therapy of chronic hepatitis C with the combination of pegylated interferon and ribavirin for 24 or 48 weeks was a remarkable accomplishment of the past decade. However, sustained virological responses rates of about 80% (genotypes 2-3) and 50% (geno 3 type 1) were not satisfactory especially for patients infected with genotype 1. Important advances in the biology of HCV have made possible the development of the direct-acting antiviral agents boceprevir and telaprevir with substantial increase in the rates of sustained virological response with shorter duration of therapy for a large number of patients. However, the complexity of triple therapy is higher and several new side effects are expected suggesting greater expertise in the patient management. Anemia and disgeusia are frequent with boceprevir while cutaneous rash, ranging from mild to severe, is expected with telaprevir. Higher risk of drug-drug interactions demand further clinical consideration of the previous well-known adverse events of pegylated interferon and ribavirin. Identification and prompt management of these potential new problems with boceprevir and telaprevir are crucial in clinical practice for optimizing treatment and assuring safety outcomes to HCV-genotype 1 patients.
publishDate 2013
dc.date.none.fl_str_mv 2013-04-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702013000200013
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702013000200013
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1016/j.bjid.2012.10.010
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Brazilian Society of Infectious Diseases
publisher.none.fl_str_mv Brazilian Society of Infectious Diseases
dc.source.none.fl_str_mv Brazilian Journal of Infectious Diseases v.17 n.2 2013
reponame:Brazilian Journal of Infectious Diseases
instname:Brazilian Society of Infectious Diseases (BSID)
instacron:BSID
instname_str Brazilian Society of Infectious Diseases (BSID)
instacron_str BSID
institution BSID
reponame_str Brazilian Journal of Infectious Diseases
collection Brazilian Journal of Infectious Diseases
repository.name.fl_str_mv Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID)
repository.mail.fl_str_mv bjid@bjid.org.br||lgoldani@ufrgs.br
_version_ 1754209242440531968